BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14660054)

  • 1. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
    Aswald JM; Lipton JH; Aswald S; Messner HA
    Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
    Aswald JM; Lipton JH; Messner HA
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
    Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
    Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
    Steegmann JL; Moreno G; Aláez C; Osorio S; Granda A; de la Cámara R; Arranz E; Reino FG; Salvanés FR; Fernández-Rañada JM; Muñoz C
    Haematologica; 2003 Jul; 88(7):762-8. PubMed ID: 12857554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
    Molnár L; Nagy A; Dávid M; Szomor A; Méhes G; Kovács G; Losonczy H
    Orv Hetil; 2004 Apr; 145(17):901-7. PubMed ID: 15170967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib.
    Kiani A; Habermann I; Schäke K; Neubauer A; Rogge L; Ehninger G
    Haematologica; 2003 Jul; 88(7):754-61. PubMed ID: 12857553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
    Kujawski LA; Talpaz M
    Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
    Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
    Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
    Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
    Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life on imatinib.
    Hahn EA; Glendenning GA
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.